Modafinil (Prescription).
Enhances wakefulness and focus, but requires a prescription. Forces wakefulness. It's designed for people with diagnosed sleep disorders like narcolepsy, not for pulling an all-nighter before a deadline.
Reviewed March 2026
- Category
- Compound
- Also filed under
- Promotes wakefulnessEnhances focus and concentration in some individuals
What Modafinil (Prescription) is, and what it does.
- Does it work
- For a diagnosed condition? Yes, under a doctor's care. For off-label 'biohacking'? No. The risks outweigh the temporary focus for most people.
- How much to take
- Prescription only. Your doctor decides. Usually starts at 100-200mg taken once in the morning.
- Time to feel it
- Alertness builds within about an hour of a morning dose and holds ten to twelve hours, since the slower R enantiomer is still clearing late in the day.
- The first dose
- You'll feel it in an hour. Increased alertness, zero desire for sleep. The effect is strong and lasts 10-12 hours.
- With regular use
- Risk of psychological dependence and disrupting your natural sleep cycle. This isn't for daily use unless prescribed for a chronic condition.
- How well tolerated
- Requires medical supervision. Can cause serious skin reactions, heart issues, and psychiatric side effects. Not for casual use.
- How it feels
- Like a clean, non-jittery focus for some. For others, it's a one-way ticket to anxiety and a headache.
- The overlooked benefit
- The detail most people miss is pharmacokinetic. It induces CYP3A4 and inhibits CYP2C19, so exposure to other things taken alongside it, hormonal contraception included, can shift.
100 to 200mg a day is where Modafinil (Prescription) works.
Source: FDA prescribing information; Minzenberg & Carter, Neuropsychopharmacology, 2008
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Modafinil's efficacy in treating specific sleep disorders is well-established through clinical trials. However, its use as a cognitive enhancer in healthy individuals has less support and more controversy.
- wakefulness during extended sleep lossMeta-analysis
- alertness across night shift hoursRandomised trial
- sustained attention in sleep-deprived adultsRandomised trial
- clearance shifts in co-administered CYP3A4 and CYP2C19 substratesRandomised trial
- half-life difference between the R and S enantiomersRandomised trial
Questions people ask about Modafinil (Prescription).
- Is this like Adderall?
- Similar outcome (focus), different mechanism. Generally considered less 'speedy' and with a lower, but still present, potential for abuse.
- Can I take it to study for an exam?
- That's off-label use. A bad idea without a doctor. A good night's sleep is probably more effective and definitely safer.
- Will it show up on a drug test?
- Yes, it can. If you don't have a prescription for it, that's a problem.
- Can I drink coffee with it?
- Not a great idea. It can amplify anxiety and heart rate. Start with a very small amount of caffeine if you must.
- Does it mess with sleep?
- Yes, that's its job. Take it first thing in the morning or you won't be sleeping that night.
- Is it addictive?
- It has a potential for dependence. Your body can get used to it, making it harder to feel normal without it.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Adrafinil is converted in the liver to modafinil itself. Taking both delivers the same active molecule by two routes rather than adding a distinct mechanism.
Caffeine antagonises adenosine receptors while modafinil acts on dopamine reuptake, so alertness effects add rather than overlap. The same addition applies to normal heart rate, blood pressure and sleep onset.
Both raise CYP3A4 expression, St John's wort through pregnane X receptor activation and modafinil through its own induction. Anything cleared by CYP3A4, including hormonal contraceptives, is lowered further when the two are taken together.
Tyrosine feeds tyrosine hydroxylase, the rate-limiting step in dopamine and noradrenaline synthesis. Raised catecholamine turnover makes precursor availability the step most likely to run short.
Alpha-2 blockade by yohimbine increases noradrenaline release into the synapse. Layered onto a wakefulness agent that already raises catecholamine tone, the cardiovascular and arousal effects add.
Theanine is an amino acid analogue of glutamate that shifts cortical alpha activity and is often stacked with wake-promoting agents to soften the jittery edge of stimulation. No combination trial was located. Read the pairing as mechanistic rather than clinical.
Melatonin signals biological evening through MT1 and MT2 receptors and shortens time to sleep onset. A wake-promoting agent pushes the same behavioural output in the opposite direction, so the two oppose each other when their timing overlaps. Separation across the day is the practical consequence.
Alpha-GPC delivers choline that choline acetyltransferase converts into acetylcholine. Wake-promoting agents act mainly on catecholamine handling, a separate arm, which is the stated rationale for stacking them for attention support. The reasoning is mechanistic and no combination study was located.
Citicoline breaks down to choline and cytidine, feeding acetylcholine synthesis and membrane phosphatidylcholine turnover. That pathway does not overlap with catecholamine reuptake. The pairing is mechanistic, not a tested combination.
Magnesium gates NMDA receptor channels and supports normal muscle relaxation. It is stacked alongside stimulating compounds on the reasoning that it offsets tension rather than adds to alertness. No combination study was located.
Ashwagandha extracts are used for calming and evening settling, while a wake-promoting agent is used for daytime alertness. Taken together in the same window the two push arousal in opposite directions. Timing separation is the sensible reading.
Rhodiola rosea preparations are described as acting on monoamine handling and perceived exertion. Stacking with a catecholamine-active compound may raise the chance of additive stimulation. No combination trial was located, so the size of any effect is unmeasured.
Bacopa bacosides are studied over weeks for memory-related outcomes and act on cholinergic and antioxidant pathways rather than on catecholamine reuptake. The two are stacked because their timescales and targets differ. This is a mechanistic pairing only.
Standardised green tea extracts usually retain caffeine unless the label says decaffeinated. Adding one to another alertness-promoting compound stacks adenosine-receptor blockade on top of catecholamine activity. Total daily stimulant load is the thing to count.
Berberine inhibits CYP3A4 in laboratory systems, and CYP3A4 is one route by which many prescription compounds are cleared. Slower clearance means higher exposure at the same dose. This is mechanistic, and the size of any shift in a person was not measured here.
Quercetin inhibits CYP3A4 and the P-glycoprotein efflux pump in laboratory systems. Both changes can raise the systemic exposure of compounds handled by those routes. In vitro inhibition is not a measured human interaction, and it is flagged here as a mechanism to be aware of.
5-HTP is decarboxylated directly to serotonin and raises serotonergic tone. Layering it onto a compound with monoamine activity changes the balance between transmitter systems in ways that were not measured together. Regard the stack as unstudied.
Talk to a doctor before taking Modafinil (Prescription) if any of these apply to you: Requires a prescription, Potential for abuse and dependence, May cause side effects like headache, nausea, anxiety, Interacts with various medications, Not recommended for individuals with heart problems or uncontrolled hypertension. These are flags to check first, not effects Modafinil (Prescription) is known to cause.
Not medical advice. Show the label to your pharmacist.What Modafinil (Prescription) actually does.
Modafinil is a racemic mixture of R and S enantiomers. The R form has a substantially longer elimination half-life than the S form, which is why the two behave differently over a day.
Modafinil induces CYP3A4 and inhibits CYP2C19. Both are clearance routes for a wide set of co-administered compounds, so exposure to those compounds can shift in either direction.
Modafinil is a prescription-only compound in most jurisdictions and is not a dietary supplement ingredient. It is documented here for interaction and formulation context, not as something to add to a formula.
Modafinil raises histaminergic, noradrenergic and orexinergic signalling in downstream animal work, which is the mechanistic account of its wake-promoting effect rather than a direct receptor action.
Where Modafinil (Prescription) comes from.
It is made in a chemical plant, not grown. Chemists build a two-ring core, attach a sulfur arm, oxidise that sulfur to exactly one stage and no further, then crystallise the powder and press it into tablets.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The benzhydryl core is built from benzhydrol, itself derived from benzophenone chemistry. These are petrochemical-derived aromatic feedstocks, not agricultural inputs.
Benzhydrol is converted to a benzhydryl thioacetic acid or thioacetamide intermediate, placing the sulfur bridge between the diphenylmethyl group and the acetamide arm.
The thioether sulfur is oxidised to the sulfinyl (sulfoxide) state. Control matters here because over-oxidation gives the sulfone, a different compound.
The crude product is recrystallised to remove the sulfone and unreacted intermediates. Where the single R enantiomer is wanted, a chiral resolution or asymmetric oxidation step is added.
The purified powder is blended with disintegrant, binder and lubricant and compressed into fixed-strength tablets under pharmaceutical manufacturing controls.
The forms it comes in.
The essence, in one line each.
- The authors surveyed randomised controlled trials of prescription and non-prescription pharmacological options and reported the evidence base as uneven across agents.Systematic review. Mehrabi S et al., 2025 (Journal of Pharmacy Technology). PMID 39564452 ↗
- The reviewers concluded that the certainty of evidence for interventions aimed at low energy in this population was low, with few trials per comparison.Systematic review. Natale P et al., 2023 (Cochrane Database of Systematic Reviews). PMID 37651553 ↗
- The authors reviewed sex differences in response to attention-related medication and reported that female participants remain under-represented in the trial record.Narrative review. Muller ED et al., 2026 (Naunyn-Schmiedebergs Archives of Pharmacology). PMID 41099844 ↗
These are the studies our verdict leans on, chosen from the 3 we read for Modafinil (Prescription). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.